Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-742-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.73 million
Profitability
Miscellaneous
Employees170
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics Inc (NASDAQ:RVNC) released its quarterly earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, meeting the consensus estimate of ($0.86). Revance Therapeutics had a negative return on equity of 79.28% and a negative net margin of 3,745.97%. View Revance Therapeutics' Earnings History.
When is Revance Therapeutics' next earnings date?
What price target have analysts set for RVNC?
11 Wall Street analysts have issued 1-year price targets for Revance Therapeutics' stock. Their predictions range from $17.83 to $50.00. On average, they anticipate Revance Therapeutics' stock price to reach $34.7288 in the next twelve months. This suggests a possible upside of 167.8% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.
What is the consensus analysts' recommendation for Revance Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.
What are Wall Street analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (8/9/2019)
- 2. Mizuho analysts commented, "We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT." (4/24/2019)
- 3. HC Wainwright analysts commented, "Our $25 price target for Revance is based on our sum of the parts NPV valuation based on each of RT-002’s targeted indications. Our DCF model utilizes a WACC-derived discount rate of 12.2% (Beta of 1.4, equity risk premium of 6.7%). We adjust each indication for probability of success with glabellar lines at 85%, cervical dystonia at 80%, plantar fasciitis at 25%, chronic migraine at 35% and upper limb spasticity at 80%." (2/14/2019)
- 4. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month price target of $50 on shares of RVNC. We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive the stock higher. RVNC’s long-duration, next-generation injectable neuromodulator may be a pipeline in a product. RT002 targets a $3B+ market opportunity for both medical and aesthetic indications." (11/1/2018)
Has Revance Therapeutics been receiving favorable news coverage?
News stories about RVNC stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Revance Therapeutics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Revance Therapeutics.
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), Portola Pharmaceuticals (PTLA), Cambrex (CBM), Xencor (XNCR), Zai Lab (ZLAB), Akcea Therapeutics (AKCA), Nabriva Therapeutics (NBRV), Zogenix (ZGNX), Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Prestige Consumer Healthcare (PBH), Apellis Pharmaceuticals (APLS) and Tricida (TCDA).
What other stocks do shareholders of Revance Therapeutics own?
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
- Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
- Dr. Abhay Joshi, Chief Operating Officer (Age 56)
- Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
- Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications
Who are Revance Therapeutics' major shareholders?
Revance Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.00%), JPMorgan Chase & Co. (5.62%), Bank of New York Mellon Corp (5.11%), Vanguard Group Inc. (5.10%), Renaissance Technologies LLC (3.02%) and Rice Hall James & Associates LLC (2.01%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail, Mark J Foley and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.
Which institutional investors are selling Revance Therapeutics stock?
RVNC stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp DE, Bank of New York Mellon Corp, BlackRock Inc., D. E. Shaw & Co. Inc., Invesco Ltd. and Quinn Opportunity Partners LLC. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche and L Daniel Browne. View Insider Buying and Selling for Revance Therapeutics.
Which institutional investors are buying Revance Therapeutics stock?
RVNC stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Nuveen Asset Management LLC, Sio Capital Management LLC, Vanguard Group Inc., Bamco Inc. NY and Point72 Asset Management L.P.. View Insider Buying and Selling for Revance Therapeutics.
How do I buy shares of Revance Therapeutics?
Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
One share of RVNC stock can currently be purchased for approximately $12.97.
How big of a company is Revance Therapeutics?
Revance Therapeutics has a market capitalization of $571.98 million and generates $3.73 million in revenue each year. The biopharmaceutical company earns $-142,570,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.View Additional Information About Revance Therapeutics.
What is Revance Therapeutics' official website?
How can I contact Revance Therapeutics?
Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]
MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
